Table 4.
Univariate and multivariate analyses of prognostic factors for overall survival in validation cohort I.
| Variables | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| Log-rank χ2 | P value | B | SE | HR | 95% CI | P value | |
| Age, years (> 56/≤ 56) | 0.442 | 0.506 | |||||
| Gender (male/female) | 0.016 | 0.899 | |||||
| Ascites (yes/no) | 11.315 | 0.001* | -0.156 | 0.195 | 0.856 | 0.586 to 1.250 | 0.423 |
| Laboratory parameters | |||||||
| ALP, U/L (> 200/≤ 200) | 6.926 | 0.008* | 0.002 | 0.177 | 1.002 | 0.709 to 1.416 | 0.991 |
| ALB, g/L (> 36/≤ 36) | 1.692 | 0.193 | |||||
| AFP, ng/dL (> 400/≤ 400) | 9.048 | 0.003* | 0.268 | 0.164 | 1.307 | 0.950 to 1.799 | 0.102 |
| BUN, mmol/L (> 8.9/≤ 8.9) | 6.608 | 0.010* | 0.725 | 0.226 | 2.064 | 1.329 to 3.206 | 0.001 |
| T category (T1-2/T3-4) | 11.450 | 0.001* | -0.252 | 0.476 | 0.778 | 0.307 to 1.969 | 0.597 |
| N category (N0/N1) | 3.384 | 0.066 | |||||
| M category (M0/M1) | 0.093 | 0.761 | |||||
| TNM (Ⅰ-II/III-IV) | 11.280 | 0.001* | 0.895 | 0.538 | 2.447 | 0.858 to 6.980 | 0.096 |
| PVTT (yes/no) | 25.406 | < 0.001* | 0.502 | 0.224 | 1.652 | 1.069 to 2.555 | 0.025 |
| Child-Pugh grade | 23.713 | < 0.001* | |||||
| A | NA | NA | 1 | Reference | NA | ||
| B | 0.385 | 0.217 | 1.470 | 0.962 to 2.246 | 0.076 | ||
| C | 1.061 | 0.290 | 2.889 | 1.640 to 5.089 | < 0.001 | ||
| AAPR (> 0.439/≤ 0.439) | 19.729 | < 0.001* | -0.759 | 0.309 | 0.468 | 0.256 to 0.855 | 0.014 |
HCC: hepatocellular carcinoma; TACE: transcatheter arterial chemoembolization; ALP: alkaline phosphatase; ALB: albumin; AFP: alpha fetoprotein; BUN: blood urea nitrogen; TNM: tumour-node-metastasis; PVTT: portal vein tumour thrombus; AAPR: albumin-to-alkaline phosphatase ratio; NA: not applicable.
* Variables with a P value less than 0.05 were entered into multivariate analysis.